[{"orgOrder":0,"company":"TeraImmune","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Baudax Bio"},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ National Institutes of Health"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by TeraImmune

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.

Product Name : TI-168

Product Type : Cell and Gene therapy

Upfront Cash : Undisclosed

June 30, 2023

Lead Product(s) : TI-168

Therapeutic Area : Genetic Disease

Highest Development Status : IND Enabling

Sponsor : Baudax Bio

Deal Size : Undisclosed

Deal Type : Acquisition

blank

02

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.

Product Name : TI-168

Product Type : Cell and Gene therapy

Upfront Cash : Undisclosed

April 01, 2023

Lead Product(s) : TI-168

Therapeutic Area : Genetic Disease

Highest Development Status : IND Enabling

Sponsor : National Institutes of Health

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolera...

Product Name : TI-168

Product Type : Cell and Gene therapy

Upfront Cash : Inapplicable

November 10, 2022

Lead Product(s) : TI-168

Therapeutic Area : Genetic Disease

Highest Development Status : IND Enabling

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank